- Home
- SDHC vs PSNL Comparison
SDHC vs PSNL Comparison
Compare SDHC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- PSNL
- Stock Information
- Founded
- SDHC 2008
- PSNL 2011
- Country
- SDHC United States
- PSNL United States
- Employees
- SDHC N/A
- PSNL N/A
- Industry
- SDHC
- PSNL Medical Specialities
- Sector
- SDHC
- PSNL Health Care
- Exchange
- SDHC Nasdaq
- PSNL Nasdaq
- Market Cap
- SDHC 794.4M
- PSNL 854.8M
- IPO Year
- SDHC 2024
- PSNL 2019
- Fundamental
- Price
- SDHC $17.29
- PSNL $6.90
- Analyst Decision
- SDHC Hold
- PSNL Strong Buy
- Analyst Count
- SDHC 4
- PSNL 5
- Target Price
- SDHC $16.63
- PSNL $9.60
- AVG Volume (30 Days)
- SDHC 99.2K
- PSNL 1.4M
- Earning Date
- SDHC 11-05-2025
- PSNL 11-04-2025
- Dividend Yield
- SDHC N/A
- PSNL N/A
- EPS Growth
- SDHC N/A
- PSNL N/A
- EPS
- SDHC N/A
- PSNL N/A
- Revenue
- SDHC $998,173,000.00
- PSNL $69,103,000.00
- Revenue This Year
- SDHC $1.27
- PSNL N/A
- Revenue Next Year
- SDHC $8.41
- PSNL $29.83
- P/E Ratio
- SDHC $78.49
- PSNL N/A
- Revenue Growth
- SDHC 10.26
- PSNL N/A
- 52 Week Low
- SDHC $15.00
- PSNL $2.83
- 52 Week High
- SDHC $37.90
- PSNL $10.95
- Technical
- Relative Strength Index (RSI)
- SDHC 49.44
- PSNL 36.41
- Support Level
- SDHC $16.65
- PSNL $9.40
- Resistance Level
- SDHC $18.58
- PSNL $10.06
- Average True Range (ATR)
- SDHC 0.82
- PSNL 0.71
- MACD
- SDHC 0.06
- PSNL -0.42
- Stochastic Oscillator
- SDHC 43.95
- PSNL 6.68
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.